{"id":"W4410049939","doi":"10.1016/j.clml.2025.04.020","title":"Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Takeda Pharmaceuticals U.S.A.; Takeda Development Center Americas","keywords":"Medicine; Internal medicine; Rituximab; Chills; Phases of clinical research; Pharmacodynamics; Gastroenterology; Lymphoma; Refractory (planetary science); Adverse effect; Oncology; Dosing; Pharmacology; Immunology; Toxicity; Pharmacokinetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009331719,0.001143801,0.001516886,0.0004091,0.0002705168,0.0007255199,0.0007508873,0.0007381267,0.00212113],"category_scores_gemma":[0.0003832723,0.0005248502,0.000735392,0.0003128782,0.0006635364,0.0005635558,0.0002960172,0.001915824,0.00060529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005211085,"about_ca_system_score_gemma":0.001037639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005539311,"about_ca_topic_score_gemma":0.001510299,"domain_scores_codex":[0.9998099,0.00009318505,0.00001020866,0.0000295903,0.00001738183,0.00003970321],"domain_scores_gemma":[0.9997086,0.00003112319,0.00006002739,0.00002282038,0.00002113953,0.0001562853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4310609,0.1369954,0.007063106,0.001676862,0.001736578,0.000583777,0.0005910471,0.005657391,0.250309,0.000516633,0.005342944,0.1584665],"study_design_scores_gemma":[0.3113776,0.6602523,0.007726782,0.00005185107,0.0006113061,0.000387721,0.0001196777,0.001992295,0.01376209,0.0002378505,0.00344729,0.00003328265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994273,0.001920784,0.0006293837,0.0002243053,0.00008071687,0.001539146,0.0003764483,0.0000766476,0.0008796299],"genre_scores_gemma":[0.991765,0.001844505,0.001588209,0.0003928829,0.00008158112,0.001821919,0.0008780966,0.0000206688,0.001607198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00212113,"threshold_uncertainty_score":0.007095873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02805496074734917,"score_gpt":0.3550067574628266,"score_spread":0.3269517967154774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}